autologous 19-28z/IL-18 CAR T lymphocytes

{
  "id": "MLC-T-ONC-011315",
  "term": "autologous 19-28z/IL-18 CAR T lymphocytes",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19) fused to the extracellular, transmembrane and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta) (19-28z), and expressing the human pro-inflammatory cytokine interleukin 18 (IL-18), with potential immunomodulating and antineoplastic activities. Upon intravenous administration, autologous 19-28z/IL-18 CAR T lymphocytes target, bind to, and induce selective toxicity in CD19-expressing tumor cells. IL-18 promotes T-cell persistence and potentiates the immune response against tumor cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. Incorporation of costimulatory signaling domains increases human T-cell function, expansion, and survival.",
  "synonyms": [
    "autologous 19-28z/IL-18 CAR T cells",
    "autologous 19-28z/IL-18 CAR-T cells",
    "autologous 19-28z/IL-18-expressing CAR T cells",
    "autologous anti-CD19 CAR-CD28-CD3zeta-IL-18-expressing T lymphocytes",
    "autologous CD19-targeting CD28-CD3zeta/IL-18-expressing CAR-T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-19-28z-il-18-car-t-lymphocytes/"
}